All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

News

Article

September 18, 2013

Judge Approves Consent Decree Against Shamrock Medical Solutions Group

Author(s):

Pharmaceutical Technology Editors

Shamrock Medical Solutions Group, a drug repackaging and distribution company, repeatedly failed to comply with good manufacturing practices.

A federal judge has approved a consent decree of permanent injunction against Shamrock Medical Solutions Group, Lewis Center, Ohio, and four of its corporate officers and employees for continued drug manufacturing and labeling violations that resulted in the distribution of mislabeled drugs, the FDA reported in a press statement on Sept. 18.

Shamrock Medical repackaged and distributed solid and liquid oral non-sterile drug products for human use to hospitals throughout the United States. FDA reported that inspections found several violations at the facility, including failure by the quality control unit to fully follow its own quality control procedures and to examine packaged and labeled products to ensure correct labeling. The FDA previously had sent warning letters to Shamrock Medical for violating cGMPs and distributing incorrectly labeled drugs.

This announcement follows an FDA alert issued in April 2013 advising health care providers to remove drugs distributed by Shamrock Medical from supply stock due to the possibility that they were mislabeled. The warning covered many non-sterile medications and dosage forms, including tablets, vials, ophthalmic and otic solutions, and patches. Shamrock Medical’s representatives informed the court that they are no longer repackaging or distributing any drugs.

According to the consent decree approved by Judge Algenon L. Marbley of the Southern District of Ohio, if Shamrock Medical decides to resume operations, the company must first notify the FDA of their intention and will not be able to resume operations until they receive written notice from the FDA that their operations are compliant with the Federal Food, Drug, and Cosmetic Act and all applicable regulations.

In addition, the company is required to retain an independent expert to inspect their operations and have the expert certify to the FDA that the necessary corrections have been made, prior to resuming operations. FDA reports it has not received reports of harm to patients from use of these drug products; the agency does not anticipate a drug shortage as a result of today’s consent decree.

Source: FDA

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
Understanding the Operational Impacts of the 15% US-EU Pharma Tariff Cap
Dave Miller, PhD, Chief Scientific Officer, AustinPx
Related Content
Advertisement
B. Braun - german medical technology company, Czech branch | Image Credit: © Solarisys - stock.adobe.com
August 24th 2025

B. Braun Medical Voluntarily Recalls Two Injections, Citing Presence of Particulate Matter

Patrick Lavery
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
August 24th 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
August 24th 2025

Johnson & Johnson Invests $2 Billion into North Carolina Facility

Susan Haigney
Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail
August 24th 2025

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
Bio/Pharma's Tariff Response: Key Insights from Industry Survey Results
August 24th 2025

Bio/Pharma's Tariff Response: Key Insights from Industry Survey Results

Christopher Cole
Mitragyna speciosa or kratom leaves with medicinal products in capsules and powder in white ceramic bowl and wooden table, top view | Image Credit: ©Yanawut Suntornkij - stock.adobe.com
August 24th 2025

Kratom and the Impact of 7-OH Reclassification

Susan Haigney
Related Content
Advertisement
B. Braun - german medical technology company, Czech branch | Image Credit: © Solarisys - stock.adobe.com
August 24th 2025

B. Braun Medical Voluntarily Recalls Two Injections, Citing Presence of Particulate Matter

Patrick Lavery
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
August 24th 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
August 24th 2025

Johnson & Johnson Invests $2 Billion into North Carolina Facility

Susan Haigney
Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail
August 24th 2025

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
Bio/Pharma's Tariff Response: Key Insights from Industry Survey Results
August 24th 2025

Bio/Pharma's Tariff Response: Key Insights from Industry Survey Results

Christopher Cole
Mitragyna speciosa or kratom leaves with medicinal products in capsules and powder in white ceramic bowl and wooden table, top view | Image Credit: ©Yanawut Suntornkij - stock.adobe.com
August 24th 2025

Kratom and the Impact of 7-OH Reclassification

Susan Haigney
About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.